Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Emmaus Life Sciences's operating assets for the quarter that ended in Mar. 2026 was $17.62 Mil. Emmaus Life Sciences's operating liabilities for the quarter that ended in Mar. 2026 was $54.36 Mil. Emmaus Life Sciences's Total Assets for the quarter that ended in Dec. 2025 was $21.44 Mil. Therefore, Emmaus Life Sciences's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was -1.71.
Emmaus Life Sciences Scaled Net Operating Assets Related Terms
Emmaus Life Sciences Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Emmaus Life Sciences's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emmaus Life Sciences Scaled Net Operating Assets Chart
EMMA vs CERO, AGTX, WINT: Scaled Net Operating Assets Comparison
For the Biotechnology subindustry, Emmaus Life Sciences's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emmaus Life Sciences Scaled Net Operating Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Emmaus Life Sciences's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of -1.71 mean?
Emmaus Life Sciences (EMMA) has a Scaled Net Operating Assets of -1.71 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Emmaus Life Sciences and its competitors.
Is Emmaus Life Sciences' Scaled Net Operating Assets too high?
Emmaus Life Sciences' current Scaled Net Operating Assets is -1.71.
How does Emmaus Life Sciences' Scaled Net Operating Assets compare to CERO and AGTX?
Emmaus Life Sciences' Scaled Net Operating Assets of -1.71 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Emmaus Life Sciences and its competitors. Emmaus Life Sciences's current Scaled Net Operating Assets is -1.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading right at its estimated fair value. The current Scaled Net Operating Assets is -1.71. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Scaled Net Operating Assets is -1.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMMA has been successfully added to your 